Published in the journal Communications Medicine and conducted by researchers at Harvard Medical School, the new study is titled Clinical and Cognitive Improvement Following a Full-Spectrum, High-Cannabidiol Treatment for Anxiety: Open Data from a Two-Phase Phase 2 Clinical Trial.
The study notes that although “evidence suggests that cannabidiol (CBD) has anxiolytic properties, indicating potential for novel treatment strategies…few clinical trials of CBD-based products have been conducted, and so far none have examined the impact of these products on cognition.”
In this open-label clinical trial, linear autoregressive modeling evaluated the efficacy and tolerability of a four-week regimen of a full-spectrum, high-CBD, low-THC extract (9.97 mg/mL CBD and 0.23 mg/mL Δ-9-tetrahydrocannabinol) in outpatients with moderate-to-severe anxiety via a CBD-rich sublingual solution.
“The findings suggest significant improvement in primary outcomes measuring anxiety and in secondary outcomes assessing mood, sleep, quality of life, and cognition (specifically executive function) following treatment,” the study states. “Anxiety is significantly reduced at week 4 relative to baseline. Clinically meaningful treatment response is achieved and maintained as early as week 1 in most patients; the cumulative frequency of patients responding to treatment reaches 100% by week 3.”
The researchers state that CBD is “well tolerated, with high patient adherence/retention and no intoxication or serious adverse effects reported. Minor side effects, such as drowsiness/fatigue, increased energy and dry mouth, are infrequently endorsed.”
The study concludes, “The results provide preliminary evidence supporting the efficacy and tolerability of a full-spectrum, high-CBD product for anxiety. Patients rapidly achieve and maintain symptom reduction with few side effects. Definitive evaluation of the impact of this novel treatment on clinical symptoms and cognition will be determined in the ongoing, double-blind, placebo-controlled phase.”